ASX Announcement 23 July 2026

Quarterly Activities Report and Appendix 4C

HIGHLIGHTS

- Organisational restructuring was completed, with an estimated annualised cost reduction of $5 million from FY2027; one-off redundancy costs of $0.8 million were settled during the quarter;
- The Company signed a 10-year agreement with Hvidovre Hospital in Denmark in April 2026 for the supply of instruments and reagents of its gastrointestinal *EasyScreen*™ product with an option to extend for an additional two years.
- A key milestone in the Hvidovre agreement, installation and validation of instrumentation, was completed in June and the first commercial order was received on 10 July 2026;
- A comprehensive strategic review was completed in June 2026 positioning the Company for growth over three horizons; *stabilising* the existing business, *optimising* resources and *scaling* through existing and new market opportunities.
- The Company completed Q4 FY2026 with $22.1 million in cash and term deposits on 30 June 2026.

Operational Update

The Company recorded sales of $3.1 million[1] for Q4 FY2026, taking full-year FY2026 revenue to $14.8 million[2]. Fourth quarter revenue was affected by several factors including a competitive market environment, changes to pricing in Australia and lower testing volumes, in part as a result of a delayed flu season. The Company's international operations performed well during the quarter.

Receipts from customers were $3.0 million for Q4 FY2026. Net operating cash outflow was $3.4 million, which included one-off redundancy payments of $0.8 million relating to the organisational restructuring. Excluding these one-off payments, the underlying operating cash outflow was $2.6 million, compared with $3.5 million in the prior quarter, reflecting early benefits of the cost reduction program. There were no material investing cash outflows during the quarter, with full-year equipment investment of $1.0 million incurred in the first three quarters. Payments of fees to Directors and Officers, including the CEO, were $0.3 million for the quarter and are included in item 1.2(e) staff costs of the Appendix 4C.

As of 30 June 2026, Genetic Signatures held a total cash balance of $22.1 million, comprising $18.1 million in cash at bank and $4.0 million in term deposits. While term deposits are classified as 'other financial assets' in the Annual Report, in accordance with accounting standards, they have been included in 'cash and cash equivalents' in the Appendix 4C, to reflect funds available to the Company for funding future operating activities.

Organisational Restructuring with Estimated Annualised Cost Reduction of $5 million from FY2027

The organisational restructuring announced in Q3 FY2026 (ASX Announcement 30 March 2026) was completed during the quarter, resulting in 30 positions being made redundant across five divisions, alongside three new positions focused on project management and outsourcing capabilities. One-off redundancy cash outflows, which included accrued leave balances of $0.8 million, were settled during Q4 FY2026 and are reflected in this Appendix 4C. Together with further operational efficiencies identified through the strategic review, the restructuring is expected to deliver estimated cost savings of $5 million

---

[1] Unaudited

[2] Unaudited

Genetic Signatures Ltd ABN 30 095 913 205
7 Eliza Street, Newtown NSW 2042
Telephone + 61 (2) 9870 7580
Email: investors@geneticsignatures.com

on an annualised basis from FY2027, supporting a leaner and more sustainable cost base as the Company executes on it strategic plan positioning the business for growth.

Transition to Outsourced Product Development

The Company continued to transition elements of its product development to specialist contract research organisations during the quarter, while maintaining core intellectual property and technical capabilities in-house (ASX Announcement, 30 March 2026). This model is intended to provide access to flexible, best-in-class product development while reducing fixed costs and improving speed to market. The approach prioritises the development and commercialisation of differentiated molecular diagnostic products with multi-jurisdictional regulatory approvals and broad commercial scalability.

Danish Supply Agreement with Hvidovre Hospital

Following the signing in April 2026 of agreements for the supply of equipment, reagents and consumables for gastrointestinal screening at Hvidovre Hospital, one of the leading public hospitals in Denmark (ASX Announcement, 15 April 2026), the installation and validation process has since been completed successfully and the first commercial order was received on 10 July 2026. The Reagent and Consumables Supply Agreement has a ten-year term, extendable for up to two 12-month periods. The agreement, combined with the outcomes of utilising the *EasyScreen*™ tests in the UK and other markets, demonstrates that the Company's pan-enteric approach delivers measurable, real-world benefits for hospital laboratories, clinicians and patients, and signals growing momentum for broader adoption of the platform across Europe.

Strategic Review

In June 2026, the Company held an investor briefing at which the outcomes of a comprehensive strategic review across all aspects of the business were presented, including human resources, operational structure and the Company's key markets of Australia, the United States and Europe. The briefing set out a strategic framework to position the company for growth over three horizons; *stabilising* the existing operations, *optimising* resources and *scaling* into existing and new markets. The framework included plans to pause and reset US operations, build on the momentum established across EMEA, and pursue opportunities in the APAC region. In addition to scaling organically, the Company will continue to seek out strategic partnerships for the development of new products and to access new markets.

Product, Pricing and Instrumentation Strategy

The Company's product and instrument portfolio as well as its pricing strategy has been reviewed with the objective of focusing on profitability, while securing long-term customer relationships.

- The Optimus Prime instrument development project has been paused indefinitely. Development of an alternative solution is well underway and options for instrument partnerships are currently being evaluated.
- Product pricing has been adjusted to retain profitable customer relationships and improve competitiveness in the ongoing tendering processes. This price adjustment is likely to result in reduction in gross margins in short term; however, it is expected to deliver improved unit economics as revenue increases and fixed costs remain stable over time.
- The Company commenced broadening its respiratory pathogen detection portfolio with new product development underway. Concurrently, development of a new enteric pathogen detection product has also been outsourced to a contract research organisation to fulfil customer requirements in Europe and open new opportunities in the APAC region.

Board Developments

Board changes announced in the March 2026 quarterly report took effect on 1 May 2026. Ms Anne Lockwood concluded her role as Interim Managing Director and continues as a Non-Executive Director and Chair of the Audit Committee, and Dr Neil Gunn resigned as a Non-Executive Director.

Genetic Signatures

Outlook

The Company enters FY2027 with a clear strategic framework positioning the business for growth. Underpinned by long-term customer contracts and focused on disciplined cost management the Company intends to pursue avenues for scaling through new products targeting existing and new markets and commercial partnerships.

The Company remains focused on advancing its *EasyScreen*™ molecular diagnostic platform with a regulatory-cleared product portfolio supported by a highly skilled senior team and strong balance sheet.

The Company remains committed to delivering shareholder value.

Subsequent Events

On 3 July 2026, BCAL Diagnostics Limited made an announcement that it is acquiring a 10.2% shareholding in the Company (ASX Announcement, 3 July 2026).

The Company's audited full-year FY2026 results will be released with the Appendix 4E and Annual Report in August 2026.

– END –

Announcement authorised by Genetic Signatures' Board of Directors

For further information, see our website (www.geneticsignatures.com) or contact us:

Maria Halasz
Chief Executive Officer
maria.halasz@geneticsignatures.com
T: +61 (0) 2 9870 7580

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics company, specialising in detecting infectious diseases, using patented **3base®** technology to simplify the genetic complexity of pathogen identification. The Company's automated diagnostic workflows accurately screen for multiple infectious pathogens with similar symptoms in a single test. Genetic Signatures' unique solutions enable laboratories to enhance diagnostic workflow and efficiencies, while reducing costs. Rapid results support infection control, appropriate patient management and disease surveillance while improving healthcare outcomes. Genetic Signatures continues to expand its global presence with direct representation in Australia, the United States and Europe, alongside international distribution partnerships.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

GENETIC SIGNATURES LIMITED

ABN	**Quarter ended ("current quarter")**
30 095 913 205	30 June 2026

Consolidated statement of cash flows	**Current quarter $A'000**	**Year to date (12 months) $A'000**
1. Cash flows from operating activities		
1.1 Receipts from customers	2,990	16,817
1.2 Payments for		
(a) research and development	(225)	(2,224)
(b) product manufacturing and operating costs	(1,905)	(7,877)
(c) advertising and marketing	(185)	(930)
(d) leased assets	(98)	(360)
(e) staff costs	(3,887)	(15,225)
(f) administration, corporate and other costs	(266)	(3,356)
1.3 Dividends received (see note 3)		
1.4 Interest received	202	1,329
1.5 Interest and other costs of finance paid	(8)	(46)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	4,604
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(3,382)	(7,268)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(109)	(1,048)
(d) investments	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	(109)	(1,048)

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Principal element of lease payments	(133)	(482)
3.10	**Net cash from / (used in) financing activities**	(133)	(482)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	25,695	30,873
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,382)	(7,268)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(109)	(1,048)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(133)	(482)
4.5	Effect of movement in exchange rates on cash held	(5)	(9)
4.6	**Cash and cash equivalents at end of period**	22,066	22,066

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	18,066	17,695
5.2	Call deposits	4,000	8,000
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	22,066	25,695

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	277
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities		
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	**Total financing facilities**		

7.5	**Unused financing facilities available at quarter end**	

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (Item 1.9)	(3,382)
8.2	Cash and cash equivalents at quarter end (Item 4.6)	22,066
8.3	Unused finance facilities available at quarter end (Item 7.5)	-
8.4	Total available funding (Item 8.2 + Item 8.3)	22,066
8.5	**Estimated quarters of funding available (Item 8.4 divided by Item 8.1)**	6.5

8.6

Answer:

Answer:

Answer:

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 23 July 2026

Authorised by: Board of Directors

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.